此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study

2026年11月2日 更新者:Ruijin Hospital

Real-World Efficacy and Safety of Sevabertinib as Second-Line or Later-Line Therapy in Patients With HER2-Mutant Advanced Non-Small Cell Lung Cancer: An Observational, Bidirectional Cohort Study

This is a single-center, observational, bidirectional cohort study evaluating the real-world effectiveness, safety, and quality of life associated with sevabertinib in Chinese adults with HER2-mutant advanced non-small cell lung cancer receiving sevabertinib as second-line or later-line therapy. The study will include both retrospectively identified patients and prospectively enrolled patients. The primary objective is to evaluate real-world progression-free survival. Additional assessments include tumor response, overall survival, safety, and patient-reported quality of life.

研究概览

研究类型

观察性的

注册 (估计的)

16

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Hainan
      • Qionghai、Hainan、中国、571400
        • 招聘中
        • Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Adult Chinese patients with unresectable locally advanced or metastatic non-squamous NSCLC harboring a documented HER2 (ERBB2) TKD activating mutation who receive sevabertinib as second-line or later-line therapy in routine clinical practice. The study includes both retrospectively identified patients and prospectively enrolled patients.

描述

Inclusion Criteria:

  1. Age ≥18 years at the index date.
  2. Unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
  3. Documented HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutation.
  4. Received at least one prior systemic therapy for advanced NSCLC. Prior HER2-targeted antibody-drug conjugate (ADC) therapy is permitted, whereas prior HER2-targeted tyrosine kinase inhibitor (TKI) therapy is not permitted.
  5. For retrospectively included participants, sufficient baseline clinical, treatment, and prior follow-up data are available.
  6. Sevabertinib treatment has been determined by the treating physician based on clinical practice, or the participant has already initiated sevabertinib at screening.

Exclusion Criteria:

  1. History of Grade 3 or higher interstitial lung disease (ILD), or evidence of any clinically active ILD.
  2. Uncontrolled comorbid diseases or conditions, including but not limited to decompensated respiratory, cardiac, hepatic, or renal disease; ongoing or active infection, including active clinical tuberculosis; renal transplantation; or psychiatric/social conditions that may limit study compliance.
  3. Unstable brain metastases.
  4. Inability to comply with the study for any reason.
  5. Receipt of another unapproved investigational drug or non-drug treatment within 30 days before the index date or during the observation period.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:OTHER

队列和干预

团体/队列
干预/治疗
Sevabertinib-Treated Cohort

Adult Chinese patients with HER2-mutant advanced non-small cell lung cancer receiving sevabertinib as second-line or later-line therapy in routine clinical practice. Treatment with sevabertinib is determined by the treating physician and is not assigned by the study protocol.

Sevabertinib is administered as part of routine clinical care, generally at a dose of 20 mg orally twice daily with food until disease progression or unacceptable toxicity, according to the treating physician's clinical judgment. Treatment is not assigned by the study protocol.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Real-World Progression-Free Survival (rwPFS)
大体时间:From the first dose of sevabertinib until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 12 months.

rwPFS is defined as the time from the first dose of sevabertinib to the first documented disease progression or death from any cause, whichever occurs first.

From the first dose of sevabertinib until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 12 months.

次要结果测量

结果测量
措施说明
大体时间
Investigator-Assessed Real-World Objective Response Rate (rwORR)
大体时间:From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.

rwORR is defined as the proportion of evaluable participants whose best overall response is complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST version 1.1.

From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
Investigator-Assessed Real-World Disease Control Rate (rwDCR)
大体时间:From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.

rwDCR is defined as the proportion of evaluable participants who achieve CR, PR, or stable disease (SD). Confirmed and unconfirmed best overall responses will be analyzed separately.

From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
6-Month and 12-Month Progression-Free Survival Rates
大体时间:At 6 months and 12 months after the first dose of sevabertinib.

The probabilities of participants being alive and free from disease progression at 6 months and 12 months after the first dose of sevabertinib.

At 6 months and 12 months after the first dose of sevabertinib.
Incidence of Treatment-Related Adverse Events
大体时间:From the first dose of sevabertinib through the last available safety assessment, up to 12 months.

The incidence of treatment-related adverse events of any grade and Grade 3 or higher will be assessed. Adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 6.0.

From the first dose of sevabertinib through the last available safety assessment, up to 12 months.
Change From Baseline in EORTC QLQ-C30 Scores
大体时间:Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.

The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) assesses cancer-related quality of life. Scores for each scale range from 0 to 100. Higher functional and global health status/quality-of-life scores indicate better functioning or quality of life, whereas higher symptom scores indicate worse symptoms.

Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
Change From Baseline in NSCLC-SAQ Total Score
大体时间:Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.

The Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) assesses NSCLC-related symptoms. The total score ranges from 0 to 20, with higher scores indicating greater symptom severity.

Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
Change From Baseline in EQ-5D-5L Index Score
大体时间:Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.

The EuroQol 5-Dimension 5-Level (EQ-5D-5L) assesses overall health status across five dimensions. Using the Chinese value set, index scores range from -0.391 to 1.000, with higher scores indicating better health status.

Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月20日

初级完成 (估计的)

2028年9月30日

研究完成 (估计的)

2028年9月30日

研究注册日期

首次提交

2026年9月27日

首先提交符合 QC 标准的

2026年10月11日

首次发布 (实际的)

2026年10月19日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • RWS2026-003

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data (IPD) are not planned to be shared with external researchers because the study uses sensitive clinical data derived from medical records and follow-up. Study data are de-identified and managed under applicable confidentiality, privacy, and institutional data security requirements, with access restricted to authorized study personnel.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅